A prospective study of α-interferon and autologous bone marrow transplantation in chronic myeloid leukemia

Haematologica

Volumn 84, Issue 8, 1999, Pages 707-715

  Meloni, Giovanna ^a   Russo, Domenico ^d   Baccarani, Michele ^c   Testoni, Nicoletta ^d   Martinelli, Giovanni ^d   Fanin, Renato ^d   Zuffa, Eliana ^b   Rosti, Gianantonio ^d   Alimena, Giuliana ^d   Saglio, Giuseppe ^d   Mandelli, Franco ^a   Tura, Sante ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d NONE

Author keywords

Bone marrow transplantation; Chronic myeloid leukemia; Interferon

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; MELPHALAN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; REMISSION; SURVIVAL RATE;

ADULT; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0032859110     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Buckner CD, Stewart P, Clift RA, et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Haematol 1978; 6:96-109.
2. Goldman JM, Catovsky D, Hows J, Spiers ASD, Galton DAG. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukemia in transformation. Br Med J 1979; i:1310-3.
3. Haines ME, Goldman JM, Worsley AM, et al. Chemotherapy and autografting for chronic granulocytic leukemia in transformation: probable prolongation of survival for some patients. Br J Haematol 1984; 58:711-21.
4. Carella AM, Podestà M, Frassoni F, et al. Collection of "normal" blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12:267-71.
5. Carlo-Stella C, Mangoni L, Piovani G, Garau D, Almici C, Rizzoli V. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994; 83:1373-80.
6. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol, 1994; 86:76-81.
7. Khouri IF, Kantarjian HM, Talpaz M, et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 1996; 17:775-9.
8. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-α in chronic myelogenous leukemia. N Engl J Med 1986; 314:1065-9.
9. Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 1992; 77:204-14.
10. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon-α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 320:820-5.
11. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymphoma 1993; 11(suppl. 1):277-80.
12. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984; 63:789-98.
13. Guerrasio A, Martinelli G, Saglio G, et al. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease free subjects who received unmanipulated allogeneic bone marrow transplantation. Leukemia 1992; 6:507-12.
14. Testoni N, Martinelli G, Farabegoli P, et al. A new method of "in cell RT-PCR" for the detection of bcr-abl transcript in chronic myeloid leukemia patients. Blood 1996; 87:3822-7.
15. Cross NCP, Lin F, Chase A, BungeyJ, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82:1929-36.
16. Martinelli G, Testoni N, Montefusco V, et al. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis. Haematologica 1998; 83:593-8.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Ass 1958; 53:454-81.
18. Hehlmann R, Ansari H, Hasford J, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 1997; 97:76-85.
19. Reiffers J, Trouette R, Marit G, et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol 1991; 77:339-45.
20. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724-32.
21. Reiffers J, GoldmanJ, Meloni G, Cahn JY, Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14:407-10.
22. Carella AM, Chimirri F, Podestà M, et al. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996; 17:201-5.
23. Coutinho LH, Chang J, Brereton ML, et al. Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study. Bone Marrow Transplant 1997; 19:969-76.
24. Dhingra K, Kurwrock R, Kantarjian H, et al. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia 1992; 6:754-60.
25. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieved complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91:126-31.
26. Kantarjian HM, Talpaz M, Andersson B, et al. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14:57-61.
27. Boqué C, Petit J, Sarrà J, et al. Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia. Bone Marrow Transplant 1996; 18:879-84.
28. Johnson RJ, Owen RG, Child JA, et al. Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim). Br J Haematol 1996; 93:863-8.
29. Petzer AL, Eaves CJ, Landsdorp PM, Ponchio L, Barnett MJ, Eaves AC. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996; 88:2162-71.
30. + cells circulating in the blood of chronic phase chronic myeloid leukemia patients. Leukemia 1997; 11:1486-92.
31. Kantarjian HM, Talpaz M, Hester J, et al. Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 1995; 13:553-9.
32. Metha J, Mijovic A, Powles R, et al. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Bone Marrow Transplant 1996; 17:25-9.
33. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068-76.
34. Talpaz M, Kantarjian H, LiangJ, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional dose chemotherapy before collection of autologous cells. Blood 1995; 85:3257-63.
35. Archimbaud E, Michallet M, Philip I, et al. Granulocyte colony-stimulating factor given in addition to interferon-α to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997; 99:678-84.
36. Brandwein JM, Dube ID, Laraya P, Keating A. Maintenance of Philadelphia-chromosome-positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia. Leukemia 1992; 6:556-61.
37. Verfaillie CM, Bhatia R, Miller W, et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87:4770-9.
38. Butturini A, Keating A, Goldman J, Gale RP. Auto-transplants in chronic myelogenous leukemia: strategies and results. Lancet 1990; 335:1255-8.
39. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82:478-95.
40. Daley GQ, Goldman JM. Autologous transplant for CML revisited. Exp Hematol 1993; 21:734-7.
41. McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343:1486-8.
42. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87:3069-76.